Miaomiao Ge
Overview
Explore the profile of Miaomiao Ge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao H, Ge M, Zhang F, Du D, Zhao Z, Shen C, et al.
Genomics
. 2024 Jul;
116(5):110899.
PMID: 39047875
Nitrogen is one of the most essential elements for plant growth and development. In this study, the growth, physiology, and transcriptome of Toona sinensis (A. Juss) Roem seedlings were compared...
2.
Patel M, Johnson M, Winer I, Arkenau H, Cook N, Samouelian V, et al.
Cancer Immunol Immunother
. 2024 Mar;
73(5):89.
PMID: 38554156
Background: Ezabenlimab (BI 754091) is a humanised monoclonal antibody targeting programmed cell death protein-1. We report results from open-label, dose-escalation/expansion, Phase I trials that evaluated the safety, maximum tolerated dose...
3.
Ge M, Tang Y, Guan Y, Lv M, Zhou C, Ma H, et al.
BMC Plant Biol
. 2024 Jan;
24(1):27.
PMID: 38172667
Background: Wheat, a crucial food crop in China, is highly vulnerable to drought stress throughout its growth and development. WRKY transcription factors (TFs), being one of the largest families of...
4.
Diallyl trisulfide inhibits gastric cancer stem cell properties through ΔNp63/sonic hedgehog pathway
Ge M, Zhu J, Yi K, Chen Y, Cao W, Wang M, et al.
Mol Carcinog
. 2023 Jul;
62(11):1673-1685.
PMID: 37477518
Gastric cancer is one of the deadliest malignant tumors, and half of the patients develop recurrences or metastasis within 5 years after eradication therapy. Cancer stem cells (CSCs) are considered...
5.
Zhang P, Li X, Lu K, Wu C, Ge M
Contemp Clin Trials
. 2023 Feb;
127:107119.
PMID: 36804045
In a recent article, Zhang et al. proposed a 2-in-1 adaptive design to seamlessly expand a selected dose, based on efficacy compared to the control arm, from a Phase 2...
6.
Lv M, Luo W, Ge M, Guan Y, Tang Y, Chen W, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36233327
WRKYs are one of the largest transcription factor (TF) families and play an important role in plant resistance to various stresses. TaWRKY133, a group I WRKY protein, responds to a...
7.
Wang X, Gu M, Gao X, Xiong X, Wang N, Li Q, et al.
BMC Health Serv Res
. 2022 Oct;
22(1):1238.
PMID: 36207708
Background: Pharmacy intravenous admixture service (PIVAS) center has emerged as an important department of hospital as it can improve occupational protection and ensure the safety and effectiveness of intravenous infusions....
8.
Xie C, Zhou X, Liang C, Li X, Ge M, Chen Y, et al.
J Exp Clin Cancer Res
. 2021 Nov;
40(1):349.
PMID: 34742339
No abstract available.
9.
Xie C, Zhou X, Liang C, Li X, Ge M, Chen Y, et al.
J Exp Clin Cancer Res
. 2021 Aug;
40(1):266.
PMID: 34429133
Background: Recently, a variety of clinical trials have shown that apatinib, a small-molecule anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including non-small cell lung cancer (NSCLC). However,...
10.
Dohner H, Symeonidis A, Deeren D, Demeter J, Sanz M, Anagnostopoulos A, et al.
Hemasphere
. 2021 Aug;
5(8):e617.
PMID: 34350385
In this phase 3 trial, older patients with acute myeloid leukemia ineligible for intensive chemotherapy were randomized 2:1 to receive the polo-like kinase inhibitor, volasertib (V; 350 mg intravenous on...